Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Dermatology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Dermatology Other
    Converting to Sirolimus From Calcineurin Inhibitors Reduces Risk of Skin Cancer in Kidney Transplant Patients: Presented at Renal Week 2009 - (DGDispatch)
    Spinosad Better Than Permethrin for Pediculosis Capitis in Children: Presented at AAP - (DGDispatch)
    Topical Onychomycosis Treatment More Effective Than Oral Treatment : Presented at EADV - (DGDispatch)
    Mycophenolate Mofetil Benefits Patients With Pemphigus Vulgaris: Presented at EADV - (DGDispatch)
    Health Canada Approves Telavancin for Complicated Skin, Skin Structure Infections - (DGNews)

    News archive

     Recent webcasts/CME - Dermatology Other
      The Prevention and Treatment of Pressure Ulcers
      Contemporary Options for the Management of Scars
      Pediatric and Adolescent Sports-Related Injuries and Ailments
      The Wound Healing Process
      Current Concepts in Healing Chronic Diabetic Foot Ulcerations

      Webcasts/CME archive

       Recent cases - Dermatology Other
        Yellow Nail Syndrome
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        Complete Remission of Severe Idiopathic Cold Urticaria on Interleukin-1 Receptor Antagonist (Anakinra)
        Ulcerative Leg Nodules in a Transplant Recipient
        Pearly Penile Papules

        Cases archive
          




        my personal edition > dermatology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Benzoyl Peroxide/Clindamycin Gel Effective for Rosacea: Presented at AAD

        By Alison Palkhivala

        SAN FRANCISCO, CA -- March 25, 2003 -- A topical gel consisting of benzoyl peroxide 5% and clindamycin 1% is effective for treatment of moderate rosacea, according to results of a double-blind, multicentre study.

        D. Breneman, MD, from University Dermatology Consultants, Cincinnati, Ohio, United States, and colleagues randomised 53 adults with stage II rosacea to treatment with a combination topical agent containing 5% benzoyl peroxide and 1% clindamycin or a placebo gel for 12 weeks. The findings were presented in a poster here on March 23rd at the 61st Annual Meeting of the American Academy of Dermatology.

        The study included patients who had between eight and 50 papules or pustules on the face, no more than two nodules and Overall Rosacea Severity Assessment (ORSA) scores of at least 2.5. Patients with concomitant acne vulgaris or seborrhea dermatitis were excluded from the study.

        By Week 6, patients using the combination gel achieved an average reduction in papules and pustules from baseline of over 70%. These reductions were maintained to the end of the 12-week trial and were significantly superior to placebo (P</=0.02).

        Patients treated with the combination gel also experienced significant improvements in symptoms of rosacea, compared with baseline scores and compared with placebo (P</=0.01 for both). Patients taking the combination gel had approximately 30% improvement in ORSA score compared with 10% in those taking the placebo. Patients' impressions of improvement were also higher among those who used the active agent versus the placebo group.

        No serious adverse events occurred in either group. The most common side effects seen in patients taking the combination gel but not the placebo were burning and itching at the application site.

        Based on these findings, the authors concluded that the 5% benzoyl peroxide and 1% clindamycin combination gel is superior to placebo for the treatment of moderate rosacea and is well tolerated.

        The study was sponsored by Dermik Laboratories.


        [Study title: Double Blind, Multicenter, Comparison Study of Combination Benzoyl Peroxide/clindamycin or Placebo in Patients with Moderate Rosacea. Abstract p43]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send